Rhythm Pharmaceuticals

Edit info

Founded: 2008

Location: Boston, MA

Employee range: 50 - 200

Clinical stage: COM

Therapy area: Multiple genetic forms of obesity

Drug types: GEN, RAR, NWL, PED

Lead product: Imcivree (setmelanotide)

Funding: $125M stock Sep 2022; $172.5M stock Feb 2021

rhythmtx.com

linkedin.com

job board

Drug notes:

Also NDA Bardet-Biedl syndrome, Alstrom syndrome, Clin3 multiple types genetic obesity, Clin3 pediatric obesity, 3 trials Clin2 multiple obesity types, weekly formulation 2 trials Clin2/Clin3 obesity

About:

Rhythm Pharmaceuticals is developing drugs that target the leptin-melanocortin signaling pathway to treat patients with obesity. Obesity is the result of many factors that disrupt energy balance, not just due to food consumption. Mutations in the melanocortin-4 receptor (MC4R) pathway are linked with hyperphagia and severe obesity. With the help of their DNA database focused on obesity, Rhythm is mapping the MC4R signaling pathway to understand the functional and clinical relevance of genetic variants to identify effective drug targets. Rhythm has already completed two Phase 3 clinical trials using setmelanotide.